BAMI:MILBanco BPM SpA Analysis
Data as of 2026-03-10 - not real-time
€11.72
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Banco BPM trades at €11.72, well below its 20‑day (≈€12.20) and 50‑day (≈€12.53) simple moving averages and also under the 200‑day SMA (≈€11.87), indicating a short‑term price weakness. The RSI of 41.7 and a bearish MACD histogram reinforce the technical downside, while the stock sits just above the identified support at €10.94, leaving limited downside cushion. On the valuation side, the trailing P/E of 8.5 is less than half the industry average of 17.3, and the price‑to‑book of 1.14 suggests the market is pricing the bank close to its net asset value. A dividend yield of 8.8% with a payout ratio of 76% makes the stock attractive for income‑focused investors, and analysts’ price targets (~€13.5) imply roughly 16% upside. Fundamentally, operating margins remain strong at 43% and ROE is healthy at 14%, but revenue has contracted 10.5% YoY, and net cash is negative after accounting for €30.4 bn of debt.
Recent news points to a positive governance shift, with minority shareholders gaining double the board seats, and analyst revisions that are reframing the investment story, both of which could bolster confidence. However, the bank’s 30‑day volatility of 35% and a max drawdown near 22% signal heightened price swings, while Italy’s macro‑economic environment adds medium‑level geographic and regulatory risk. Overall, the stock appears undervalued with solid dividend income, but investors should weigh the earnings slowdown and elevated volatility.
Recent news points to a positive governance shift, with minority shareholders gaining double the board seats, and analyst revisions that are reframing the investment story, both of which could bolster confidence. However, the bank’s 30‑day volatility of 35% and a max drawdown near 22% signal heightened price swings, while Italy’s macro‑economic environment adds medium‑level geographic and regulatory risk. Overall, the stock appears undervalued with solid dividend income, but investors should weigh the earnings slowdown and elevated volatility.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with bearish momentum
- High dividend yield providing immediate return
- Elevated short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation discount vs peers (low P/E)
- Analyst price targets indicating ~16% upside
- Improved governance and positive analyst sentiment
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustainable dividend yield and solid ROE
- Stable earnings margins despite revenue dip
- Undervalued balance‑sheet metrics relative to industry
Key Metrics & Analysis
Financial Health
Revenue Growth-10.50%
Profit Margin37.42%
P/E Ratio8.5
ROE13.93%
ROA1.04%
P/B Ratio1.1
Industry P/E17.3
Technical Analysis
TrendNeutral
RSI41.7
Support€10.94
Resistance€13.06
MA 20€12.20
MA 50€12.54
MA 200€11.87
MACDBearish
VolumeStable
Fear & Greed Index76.91
Valuation
Target Price€13.65
Upside/Downside16.47%
GradeUndervalued
TypeValue
Dividend Yield8.80%
Risk Assessment
Beta0.60
Volatility35.41%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.